Pediatric-to-Adult Transition of Care in Patients with Surfactant Metabolism Disorders
Open Access
- 6 October 2026
- journal article
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
Abstract
Genetic disorders of surfactant metabolism, caused by pathogenic variants in the surfactant-related genes (SRGs) SFTPB, ABCA3, SFTPC, and NKX2-1, were long considered diseases of the neonate and the infant, with an outcome measured in weeks or months. Advances in neonatal intensive care, increased awareness, earlier molecular diagnosis, structured management, and pediatric lung transplantation have generated a growing population of adolescents and young adults living with a surfactant metabolism disorder. In the largest European survey of childhood interstitial lung disease (chILD) survivors, surfactant-related disorders accounted for about one in five patients now followed in adult centers. These patients must leave pediatric services that have often known them for many years, entering adult respiratory care systems, which are primarily around fibrotic lung disease of older adults: a setting where SRG diseases are rarely recognized. No literature is specifically devoted to transition in surfactant metabolism disorders. Therefore, this review brings together three bodies of evidence: the pediatric natural history of SFTPB, ABCA3, SFTPC, and NKX2-1-related disorders; specificities of SRG ILD surviving into and/or presenting in adulthood; the general principles of transition in rare disease, including the recent European Respiratory Society (ERS) statement on transition of care in chILD and what each implies for this group. Finally, the patient and family perspective was discussed, based on very sparse qualitative research. A proposed framework and a research agenda were suggested.Keywords
This publication has 79 references indexed in Scilit:
- Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD‐ONPediatric Pulmonology, 2026
- International Registry of NKX2‐1 ‐Related Disorders: Clinical, Genetic, and Imaging PerspectivesMovement Disorders, 2026
- Phenotype‐Genotype Correlations in ABCA3 Patients—The RespiRare CohortPediatric Pulmonology, 2025
- Cyclosporine A in children with ABCA3 deficiencyPediatric Pulmonology, 2024
- The significance of multidisciplinary team meetings in diagnosing and managing childhood interstitial lung disease within the RespiRare networkPediatric Pulmonology, 2023
- The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohortPediatric Pulmonology, 2023
- Experiences of UK‐based adult transition services for interstitial lung disease in childhood: “There's a lot less cushioning”Pediatric Pulmonology, 2023
- Childhood interstitial lung disease: Family experiencesPediatric Pulmonology, 2015
- Natural history of five children with surfactant protein C mutations and interstitial lung diseasePediatric Pulmonology, 2013
- NKX2-1mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in “Brain-Lung-Thyroid Syndrome”Human Mutation, 2010